Siliq OverviewBrodalumab (US trade name Siliq Europe Kyntheum ) is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017 it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. Use is linked to an increased risk of suicide. Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. (This mechanism is s...
Read more Siliq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brodalumab
Recent Siliq Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 210mg/1.5ml
NDC Database Records for Siliq: (1 result)Sorted by National Drug Code
- 0187-0004 Siliq 210 mg Subcutaneous Injection by Valeant Pharmaceuticals North America LLC